Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating

Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.